a leader in the worldwide diabetes and obesity care market, has been witnessing stellar performance of its GLP-1 agonist, semaglutide. Apart from the oral formulation of the drug sold as Rybelsus ...

It’s hard to watch the news or scroll through social media without encountering stories about weight loss drugs like ...

So what is semaglutide and who uses it in India? Semaglutide belongs to the class of drugs called Glucagon-like peptide-1 ...

The survey of 1,078 adults, carried out by Ipsos, found 24% of people would use weight-loss jabs if they were provided for ...

"Oral GLP-1 receptor agonist Rybelsus reduces risk of cardiovascular events in type 2 diabetes patients" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

under the brand name Rybelsus. It is indicated for adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise. As part of the ...

The study included 9,650 patients with type 2 diabetes who also have cardiovascular complexities or chronic kidney disease. According to data from the trial, Rybelsus helped reduce the risk of ...

The FDA warns GLP-1 weight loss drug users of aspiration risks during anaesthesia Learn what this update means and how to stay safe before surgeries ...

As the FDA issues a new warning about aspiration across all GLP-1 weight loss drugs, doctor groups are giving new ...